CA2479652A1 — Crystalline micronisate of tiotropium bromide
Assigned to Boehringer Ingelheim Pharma GmbH and Co KG · Expires 2003-09-25 · 23y expired
What this patent protects
The invention relates to a micronized crystalline (1alpha, 2beta, 4beta, 5alpha, 7beta)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9- azoniatricyclo[3.3.1.02,4]nonane bromide, methods for the production thereof , and the use thereof for producing a medicament, particul…
USPTO Abstract
The invention relates to a micronized crystalline (1alpha, 2beta, 4beta, 5alpha, 7beta)-7-[(hydroxydi-2-thienylacetyl)oxy]-9,9-dimethyl-3-oxa-9- azoniatricyclo[3.3.1.02,4]nonane bromide, methods for the production thereof , and the use thereof for producing a medicament, particularly for producing a medicament having an anticholinergic effect.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.